Mark T. Iwicki - Feb 24, 2025 Form 4 Insider Report for Q32 Bio Inc. (QTTB)

Role
Director
Signature
/s/ Eric Bell, Attorney-in-Fact
Stock symbol
QTTB
Transactions as of
Feb 24, 2025
Transactions value $
$0
Form type
4
Date filed
2/26/2025, 09:57 PM
Previous filing
Feb 25, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QTTB Stock Option (Right to Buy) Disposed to Issuer $0 -37.2K -100% $0.00 0 Feb 24, 2025 Common Stock 37.2K $7.29 Direct F1, F2
transaction QTTB Stock Option (Right to Buy) Award $0 +37.2K $0.00 37.2K Feb 24, 2025 Common Stock 37.2K $2.54 Direct F1, F2, F3
transaction QTTB Stock Option (Right to Buy) Disposed to Issuer $0 -7.62K -100% $0.00 0 Feb 24, 2025 Common Stock 7.62K $7.29 Direct F1, F2
transaction QTTB Stock Option (Right to Buy) Award $0 +7.62K $0.00 7.62K Feb 24, 2025 Common Stock 7.62K $2.54 Direct F1, F2, F3
transaction QTTB Stock Option (Right to Buy) Disposed to Issuer $0 -25.5K -100% $0.00 0 Feb 24, 2025 Common Stock 25.5K $16.82 Direct F1, F2
transaction QTTB Stock Option (Right to Buy) Award $0 +25.5K $0.00 25.5K Feb 24, 2025 Common Stock 25.5K $2.54 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2 This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
F3 The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.